Scientific publications
Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT. Scientific Publication
Donal P McLornan 1 , Luuk Gras 2 , Ivonne Martin 2 , Tiarlan Sirait 3 , Thomas Schroeder 4 , Igor Wolfgang Blau 5 , Jürgen Kuball 6 , Jenny Byrne 7 , Matthew Collin 8 , Michael Stadler 9 , Déborah Desmier 10 , Urpu Salmenniemi 11 , Pavel Jindra 12 , Natalia Mikhailova 13 , Stig Lenhoff 14 , Jose Rifón 15 , Marie Robin 16 , Montserrat Rovira 17 , Hendrik Veelken 18 , Alicja Sadowska-Klasa 19 , Marco Zecca 20 , Patrick J Hayden 21 , Tomasz Czerw 22 , Juan Carlos Hernández-Boluda 23 , Ibrahim Yakoub-Agha 24
Hypereosinophilic syndrome (HES) and chronic eosinophilic leukaemia (CEL), not otherwise specified (NOS) are rare haematological disorders.1 Allogeneic haematopoietic cell transplantation (allo-HCT) has been reported in single case reports or small case series only for both refractory HES or CEL, NOS and outcomes remain ill-defined.1-3 HES normally demonstrates a male predominance, likely underrecognized, with a variable clinical course.
Fulminant cases, however, are frequently associated with significant morbidity and indeed mortality. Even less common, CEL, NOS is an extremely rare myeloproliferative neoplasm (MPN), frequently demonstrating an aggressive clinical course with significant rates of acute transformation.
We hereby report outcomes from a retrospective, European Group for Blood and Marrow Transplantation (EBMT)-registry-based study of 77 adult patients with a confirmed diagnosis of either HES or CEL, NOS who underwent allo-HCT, representing the largest cohort reported to date.
CITATION Br J Haematol. 2022 Jul;198(1):209-213. doi: 10.1111/bjh.18219. Epub 2022 Apr 28
Our authors
